Get started
Author

Teodora Festini

Observed names: Festini, Teodora, T Festini, T. Festini
OpenAlex ID: A5114635892
Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site
2019 · Iris Usach, Rafael Martinez, et al. · Advances in Therapy · 358
PDF
Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)
2021 · Andrew Blauvelt, Craig L. Leonardi, et al. · BioDrugs · 20
PDF
Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
2025 · Matthias Augustin, April Armstrong, et al. · Dermatology and Therapy · 5
PDF
Real-world Effectiveness of Tralokinumab in Adults with Atopic Dermatitis: Interim Data on Improvements in Patients with Head and Neck Atopic Dermatitis after up to 9 Months of Treatment in the TRACE Study
2025 · April Armstrong, Ahmed Ameen, et al. · SKIN The Journal of Cutaneous Medicine · 3
PDF
Real-world Effectiveness of Tralokinumab in Adults with Atopic Dermatitis on the Genitals: Interim Data on Improvements in Physician-Assessed Disease Severity and Patient-Reported Outcomes in up to 3 Months of Treatment in the TRACE Study
2025 · Esther Serra-Baldrich, April W. Armstrong, et al. · SKIN The Journal of Cutaneous Medicine · 1
PDF
Real-world characterization of early and delayed responses to tralokinumab among patients with atopic dermatitis: Results from the prospective, international, non-interventional 12-month TRACE study
2026 · April W Armstrong, Jose Juan Pereyra Rodriguez, et al.
Tralokinumab Versus Dupilumab for the Treatment of Atopic Dermatitis with Moderate-to-Severe Hand Involvement: A Matching-Adjusted Indirect Comparison
2026 · Adis Journals on behalf of, April Armstrong, et al. · Figshare
Tralokinumab Versus Dupilumab for the Treatment of Atopic Dermatitis with Moderate-to-Severe Hand Involvement: A Matching-Adjusted Indirect Comparison
2026 · April Armstrong, Leon Kircik, et al. · Dermatology and Therapy
PDF
Real-world effectiveness and safety of 12 months of tralokinumab in patients with atopic dermatitis
2026 · Adis journals on behalf of:, April W Armstrong, et al. · Figshare
Real-World Effectiveness and Safety of 12 Months of Tralokinumab in Patients with Atopic Dermatitis
2026 · April W. Armstrong, Ahmed Ameen, et al. · Dermatology and Therapy
PDF
74527 Minimal disease activity with 12 months of tralokinumab treatment in adults with atopic dermatitis: Real-world data from the prospective, non-interventional, international, TRACE study
2026 · Andrew E. Pink, Elena Pezzolo, et al. · Journal of the American Academy of Dermatology
77199 Real-world effectiveness of 12 months tralokinumab treatment in patients with skin of color and moderate-to-severe atopic dermatitis: Final data from the prospective, non-interventional, international, TRACE study
2026 · April W. Armstrong, Cory Rubin, et al. · Journal of the American Academy of Dermatology
A Response to: “Letter to the Editor Regarding ‘Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis’”
2026 · Matthias Augustin, April W. Armstrong, et al. · Dermatology and Therapy
PDF
P132 Safety and effectiveness of tralokinumab treatment in adults with atopic dermatitis who previously discontinued dupilumab due to the adverse event conjunctivitis: 12-months real-world data from the TRACE study
2026 · April W Armstrong, Cory Rubin, et al. · British Journal of Dermatology
Real-World Effectiveness of Up to 12-Month Tralokinumab Treatment in Adults With Atopic Dermatitis Who Previously Discontinued Dupilumab or Janus Kinase Inhibitors
2026 · April Armstrong, Adrian Rodriguez, et al. · SKIN The Journal of Cutaneous Medicine
PDF
Tralokinumab versus Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis with Hand Involvement: a Matching-Adjusted Indirect Comparison
2026 · April Armstrong, Leon Kircik, et al. · SKIN The Journal of Cutaneous Medicine
PDF
Real-World Safety and Effectiveness of Up to 12 Months of Tralokinumab Treatment in Adults With Atopic Dermatitis Who Discontinued Dupilumab Due to Conjunctivitis
2026 · April Armstrong, Cory Rubin, et al. · SKIN The Journal of Cutaneous Medicine
PDF
Safety and Adverse Events of Special Interest in 825 Adults With Atopic Dermatitis Receiving Up to 12 Months of Tralokinumab Treatment in a Real-World Setting
2026 · Cory Rubin, Abel Jarell, et al. · SKIN The Journal of Cutaneous Medicine
PDF
Real-world Effectiveness of Tralokinumab in Adults with Atopic Dermatitis: Interim Data on Improvements in Patients with Atopic Dermatitis with Hands and Feet Involvement after up to 9 Months of Treatment in the TRACE Study
2025 · Diamant Thaçi, Pierre André Becherel, et al. · SKIN The Journal of Cutaneous Medicine
PDF
Efficacité en vie réelle du tralokinumab chez les adultes atteints de dermatite atopique : résultats intermédiaires sur l’amélioration de la sévérité de la maladie évaluée par le médecin après un suivi allant jusqu’à 9 mois dans l’étude TRACE
2024 · F. Skowron, E. Pezzolo, et al. · Annales de Dermatologie et de Vénéréologie - FMC
Efficacy and safety of mirikizumab as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis: Summary results from the Phase 3 LUCENT-1 and LUCENT-2 trials
2022 · S Howaldt, T Kobayashi, et al. · Zeitschrift für Gastroenterologie
Works count: 24
Citation count: 388
H-index: 3
I10-index: 2
Year
Topic
Type